Interferons in Cancer Therapy: From Clinical Trials to New Potentials in Anticancer Drug Discovery and Development

  • Gerhard G. Steinmann
  • Gunther R. Adolf
  • Gerhard Leitz
Chapter
Part of the Developments in Oncology book series (DION, volume 74)

Abstract

Interferons are naturally occurring proteins and share antiviral, immunomodulatory, and antiproliferative properties. They can be subdivided into 2 classes according to their acid stability. The first class which is acid-proof consists of 3 families; alpha, beta, and omega. The second class consists of interferon gamma which is not acid-proof (Table 1). Since the discovery and naming of Interferon by Isaacs and Lindenmann in 1957, Boehringer Ingelheim has for three decades now been a part of the world-wide interferon research, involving virology, immunology, cell biology, molecular genetics, biotechnological production, as well as experimental and clinical oncology. In the last few years, interferons have come of age and have found a respectable position among the most prominent new drugs.

Keywords

Fatigue Toxicity Lymphoma Leukemia Oncol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Isaacs A, Lindenmann J: Virus interference 1. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147:258–267, 1957.PubMedCrossRefGoogle Scholar
  2. 2.
    Strander H: Interferon treatment of human neoplasia. In: Advances in Cancer Research, G Klein and S Weinhouse (eds), Academic Press, Orlando, pp. 66–68, 1986.Google Scholar
  3. 3.
    Goeddel DV, Leung DW, Dull TJ, et al: The structure of eight distinct cloned human leukocyte interferon cDNAs. Nature 290:20–26, 1981.PubMedCrossRefGoogle Scholar
  4. 4.
    Streuli M, Nagata S, Weissmann C: At least three human type α interferons: Structure of α2. Science 209:1343–1347, 1980.PubMedCrossRefGoogle Scholar
  5. 5.
    Trent JM, Olsson S, Lawn, RM: Chromosomal localization of human leukocyte, fibroblast, and immune interferon genes by means of in situ hybridization. Proc. Natl. Acad. Sc. USA 79:7809–7813, 1982.CrossRefGoogle Scholar
  6. 6.
    Dworkin-Rastl E, Dworkin, MB, Swetly, P Molecular cloning of human alpha and beta interferon genes from Namalwa cells. J. Interferon Res. 2:575–585, 1982.PubMedCrossRefGoogle Scholar
  7. 7.
    Dworkin-Rastl E, Swetly, P, Dworkin, MB: Construction of expression plasmids producing high levels of human leukocyte-type interferon in Escherichia coli. Gene 20:237–248, 1983.CrossRefGoogle Scholar
  8. 8.
    Oberg K: Long-term treatment with alpha interferons of patients with malignant carcinoid tumors the six years experience. J. Interferon Res. 8: S22 (abstract), 1988.Google Scholar
  9. 9.
    Paganelli KA, Evan SS, Han T, Ozer T: B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type 1 interferon in vitro. Blood 67:937–942, 1986.PubMedGoogle Scholar
  10. 10.
    Sigaux F, Castaigne S, Lehn P, et al: Alpha-interferon in hairy cell leukaemia: Direct effects on hairy cells or indirect cytotoxicity? Int. J. Cancer 1:2–8, 1987.CrossRefGoogle Scholar
  11. 11.
    Genot E, Billard C, Sigaux F, et al: Proliferative response of hairy cells to B cell growth factor (BCGF): In vivo inhibition by interferon-a and in vitro effects of interferon-α, -ß and gamma. Leukemia 1:590–596, 1987.PubMedGoogle Scholar
  12. 12.
    Fattorossi A, Dolei A, Pizollo JG, et al: Recombinant interferon alpha-2 modulates hairy cell phenotype “in vitro”. J. Biol. Regulators and Homeostatic Agents 1:87–92, 1987.Google Scholar
  13. 13.
    Verma DS, Spitzer G, Gutterman JU: Human leukocyte interferon blocks granulopoietic differentiation. Blood 54:1423–1427, 1978.Google Scholar
  14. 14.
    Neumann HA, Fauser AA: Effect of interferon on pluripotent hemopoietic progenitors (CFU-GEMM) derived from human bone marrow. Exp. Hematol. 10:587–590, 1982.PubMedGoogle Scholar
  15. 15.
    Oladipupo-Williams CK, Svet-MoIdavskaya I, Bilchek J: Inhibitory effects of human leukocyte and fibroblast interferons on normal and chronic myelogenous leukemic granulocytic progenitor cells. Oncology 38:356–360, 1981.CrossRefGoogle Scholar
  16. 16.
    Standardization of interferons. Report of a WHO Informal Consultation. WHO Expert Committee on Biological Standardization. Thirty-fifth report, Technical Report Series 725, World Health Organization, Geneva, pp. 29–64, 1985.Google Scholar
  17. 17.
    Tanaka T, Craig AW: Cell-free transmission of murine myeloid leukaemia. Eur. J. Cancer 6:329, 1970.PubMedGoogle Scholar
  18. 18.
    DePaoli A, Johnson DO, Noll WW: Granulocytic leukemia in white-handed gibbons. JAVMA 163:624–628, 1973.Google Scholar
  19. 19.
    Chen B D-M, Najor F: Macrophage activation by interferon α and ß is associated with a loss of proliferative capacity. Cell Immunol. 106:343–354, 1987.PubMedCrossRefGoogle Scholar
  20. 20.
    Bocci V: Central nervous system toxicity of interferons and other cytokines. J. Biol. Regulators Homeostatic Agents 2:107–118, 1988.Google Scholar
  21. 21.
    Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res. 50:3473–3486, 1990.PubMedGoogle Scholar
  22. 22.
    Taylor C, Modiano M, Alberts D, et al: Combination therapy with 5-fluorouracil (5-Flu), Leucovorin (LCV) and interferon-alpha (IFN-a) in patients with adenocarcinoma. Proc. ASCO 10:141, 1991.Google Scholar
  23. 23.
    Figlin RM, Itri LM: Anti-interferon antibodies: A perspective. Sem. Hematol. 25:9–15, 1988.Google Scholar
  24. 24.
    Figlin RA, deKernion JB, Mukamel E, et al: Recombinant interferon alpha-2a in metastatic renal cell carcinoma: Assessment of antitumor activity and anti-interferon antibody formation. J. Clin. Oncol. 6:1604–1610, 1988.PubMedGoogle Scholar
  25. 25.
    Inglada L, Porres JC, LaBanda F, et al: Anti-IFN-alpha titres during interferon therapy. Lancet ii:1521, 1987.CrossRefGoogle Scholar
  26. 26.
    Itri LM, Campion M, Denning RA, et al: Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alpha-2a by intramuscular injection. Cancer 59: 668–674, 1987.PubMedCrossRefGoogle Scholar
  27. 27.
    Jacobs SL, Kelsey DK: Antibodies in patients with hairy-cell leukemia receiving alpha-2b interferon. N. Engl. J. Med. 315:1418, 1986.PubMedGoogle Scholar
  28. 28.
    Oberg K, Alm G: Development of neutralizing interferon antibodies after treatment with recombinant interferon alpha-2b in patients with malignant carcinoid tumors. J. Interferon Res. 9:S45–S49, 1989.PubMedGoogle Scholar
  29. 29.
    Panem S, Vilcek J: Antibodies to interferon in man. In: The Biology of the Interferon System. E De Mayer and H Schellekens (eds), Elsevier, Amsterdam, pp. 369–378, 1983.Google Scholar
  30. 30.
    Quesada JR, Rios A, Swanson D, et al: Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J. Clin. Oncol. 3:1522–1528, 1985.PubMedGoogle Scholar
  31. 31.
    Schmidt H, Heidemann E, Vallbracht A, Waller HD: Antibodies to human leukocyte interferon alpha after half a year of interferon treatment. Tumordiagnostik & Therapie 6:37–41, 1985.Google Scholar
  32. 32.
    Spiegel RJ, Spicehandler JR, Jacobs SL, Oden EM: Low incidence of serum neutralizing factor in patients receiving recombinant alpha-2b interferon (Intron A). Am. J. Med. 80:223–228, 1986.PubMedCrossRefGoogle Scholar
  33. 33.
    Steis RG, Smith II JW, Urba W, et al: Resistance to recombinant interferon alpha-2a in hairy cell leukaemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med. 318:1409–1413, 1988.PubMedCrossRefGoogle Scholar
  34. 34.
    Von Wussow P, Freund M, Block B, et al: Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. Lancet ii:635–636, 1987.CrossRefGoogle Scholar
  35. 35.
    Von Wussow P, Freund M, Dahle S, et al: Immunogenicity of different types of interferons in the treatment of hairy-cell leukemia. N. Engl. J. Med. 319:1226–1227, 1988.Google Scholar
  36. 36.
    Mogensen KE, Daubas PH, Gresser I, et al: Patient with circulating antibodies to alpha-interferon. Lancet ii:1227–1228, 1981.CrossRefGoogle Scholar
  37. 37.
    Trown PW, Denning Jr RA, Kramer MJ, et al: Antibodies to human leucocyte interferons in cancer patients. Lancet i:81–84, 1983.CrossRefGoogle Scholar
  38. 38.
    Ouesada JR, Itri L, Guttermann JU: Alpha interferons in hairy cell leukemia (HCL): A five year follow up of 100 patients. J. Interferon Res. 67:678, 1987.Google Scholar
  39. 39.
    Von Wussow P, Pralle H, Jakschies D, Deicher H: Resistance due to high-titered rlFN-alpha-antibodies can be overcome by nIFN-alpha in hairy cell leukemia. VI. European Interferon Workshop, How to optimize IFN-therapy, Hanover, pp. 23, 1991.Google Scholar
  40. 40.
    Itri LM, Sherman MI, Palleroni AV, et al: Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alpha-2a. J. Interferon Res. 9:9–16, 1989.Google Scholar
  41. 41.
    Prummer O, Porzsolt F (for the Delta-P Study Group): Interferon (IFN)-alpha antibody formation during adjuvant IFN-alpha-2a treatment of renal cancer. VI. European Interferon Workshop, How to optimize IFN-therapy, Hanover, p. 20, 1991.Google Scholar
  42. 42.
    Spiegel RJ, Jacobs SL, Treuhaft MW: Anti-interferon antibodies to Interferon alpha-2b: Results of comparative assays and clinical perspective. J. Interferon Res. 9:14–17, 1989.Google Scholar
  43. 43.
    Von Wussow P, Jakschies D, Freund M, Deicher H: Humoral response to recombinant interferon alpha-2b in patients receiving recombinant interferon alpha-2b therapy. J. Interferon Res. 9:25–31, 1989.Google Scholar
  44. 44.
    Weck PK, Lewenthal BG, Brandt C, Finter NB: Detection and incidence of neutralizing antibodies to interferon alpha-nl. J. Interferon Res. 9:37–43, 1989.Google Scholar
  45. 45.
    Van Regenmortel MHV: Structural and functional approaches to the study of protein antigenicity. Immunol. Today 10:266–272, 1989.PubMedCrossRefGoogle Scholar
  46. 46.
    Geysen HM, Mason TJ, Rodda SJ: Cognitive features of continuous antigenic determinants. J. Mol. Recognition 1:32–41, 1988.CrossRefGoogle Scholar
  47. 47.
    Getzoff ED, Tainer JA, Lerner RA, Geysen HM: The chemistry and mechanism of antibody binding to protein antigens. Adv. Immunol. 43:1–89, 1988.PubMedCrossRefGoogle Scholar
  48. 48.
    Adolf GR, Maurer-Fogy I, Kalsner I, Cautell KJ: Purification and characterization of natural human interferon-wl. Biol. Chem. 265:9290–9295, 1990.Google Scholar
  49. 49.
    Adolf GR: Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) wl: Evidence that IFN-wl is a component of human leukocyte IFN. Virology 175:410–417, 1990.PubMedCrossRefGoogle Scholar
  50. 50.
    Capon DJ, Shepard HM, Goeddel DV: Two distinct families of human and bovine interferon-alpha genes are coordinately expressed and encode functional polypeptides. Mol. Cell. Biol. 5:768–779, 1985.PubMedGoogle Scholar
  51. 51.
    Adolf GR: Antigenic structure of human interferon-wl (interferon alphaII1) : Comparison with other human interferons. J. Gen. Virol. 68:1669–1676, 1987.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Gerhard G. Steinmann
  • Gunther R. Adolf
  • Gerhard Leitz

There are no affiliations available

Personalised recommendations